Dyne Therapeutics Q3 net loss beats expectations

Dyne Therapeutics

05/11/2025 22:41

Overview

Dyne Q3 net loss of $108 mln beats analyst expectations

EPS for Q3 beats analyst estimates

Company reaffirms cash runway into Q3 2027

Outlook

Dyne expects topline data for z-rostudirsen in December 2025

Company anticipates U.S. launch of z-rostudirsen in Q1 2027

Dyne expects U.S. launch of z-basivarsen in Q1 2028

Result Drivers

BREAKTHROUGH DESIGNATION - FDA granted Breakthrough Therapy Designation to z-rostudirsen for DMD, aiding potential accelerated approval

CLINICAL TRIAL EXPANSION - Dyne expanded ACHIEVE trial sites in the U.S., expecting full enrollment in early Q2 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Beat
-$0.76
-$0.84 (14 Analysts)
Q3 Net Income
Beat
-$108.04 mln
-$117.30 mln (11 Analysts)
Q3 Basic EPS
-$0.76
Q3 Operating Expenses
$113.89 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Dyne Therapeutics Inc is $38.00, about 43.4% above its November 4 closing price of $21.52

Press Release: ID:nGNX3S7pfb

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)